Gilead Sciences, Inc. (GILD)
150.93
+1.24
(+0.83%)
USD |
NASDAQ |
Sep 25, 16:00
151.10
+0.17
(+0.11%)
After-Hours: 19:59
Gilead Sciences Price to Book Value : 15.83 for Sept. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 15.83 |
| September 24, 2026 | 15.70 |
| September 23, 2026 | 15.88 |
| September 22, 2026 | 16.02 |
| September 21, 2026 | 15.80 |
| September 18, 2026 | 15.75 |
| September 17, 2026 | 15.83 |
| September 16, 2026 | 15.49 |
| September 15, 2026 | 15.35 |
| September 14, 2026 | 15.36 |
| September 11, 2026 | 15.08 |
| September 10, 2026 | 15.19 |
| September 09, 2026 | 15.28 |
| September 08, 2026 | 15.38 |
| September 04, 2026 | 15.84 |
| September 03, 2026 | 15.86 |
| September 02, 2026 | 15.70 |
| September 01, 2026 | 15.73 |
| August 31, 2026 | 15.35 |
| August 28, 2026 | 15.28 |
| August 27, 2026 | 15.62 |
| August 26, 2026 | 15.54 |
| August 25, 2026 | 15.61 |
| August 24, 2026 | 15.39 |
| August 21, 2026 | 15.33 |
| Date | Value |
|---|---|
| August 20, 2026 | 15.05 |
| August 19, 2026 | 15.48 |
| August 18, 2026 | 15.05 |
| August 17, 2026 | 14.57 |
| August 14, 2026 | 14.52 |
| August 13, 2026 | 14.49 |
| August 12, 2026 | 14.25 |
| August 11, 2026 | 14.24 |
| August 10, 2026 | 13.96 |
| August 07, 2026 | 13.98 |
| August 06, 2026 | 13.73 |
| August 05, 2026 | 13.82 |
| August 04, 2026 | 14.19 |
| August 03, 2026 | 13.76 |
| July 31, 2026 | 13.66 |
| July 30, 2026 | 13.77 |
| July 29, 2026 | 13.92 |
| July 28, 2026 | 14.09 |
| July 27, 2026 | 13.69 |
| July 24, 2026 | 13.57 |
| July 23, 2026 | 13.73 |
| July 22, 2026 | 13.67 |
| July 21, 2026 | 13.67 |
| July 20, 2026 | 13.98 |
| July 17, 2026 | 14.09 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| Regeneron Pharmaceuticals, Inc. | 2.570 |
| Vertex Pharmaceuticals, Inc. | 6.584 |
| Amgen, Inc. | 19.18 |
| Biogen, Inc. | 1.784 |
Price to Book Value Related Metrics
| PS Ratio | 6.182 |
| Price to Free Cash Flow | 14.59 |
| Price | 150.93 |
| Earnings Yield | -1.76% |
| Market Cap | 187.30B |
| Operating PE Ratio | 15.83 |
| Normalized PE Ratio | 31.76 |